Yehualashet Awgichew Shewasinad, Belachew Teshome Fentik
Pharmacology and Toxicology Unit, Department of Pharmacy, College of Health Sciences, Debre Berhan University, Debre Berhan, Ethiopia.
Department of Pharmacy, Debre Birhan Health Science College, Debre Birhan, Ethiopia.
Infect Drug Resist. 2020 Sep 16;13:3217-3224. doi: 10.2147/IDR.S264882. eCollection 2020.
Although some animal studies suggested that the use of ACEIs/ARBs could contribute for the prevention and treatment of the effects of the COVID-19 infection, there are also contradictory scenarios indicating that their use may exacerbate the deleterious conditions of the infection. As a result of the paradoxical issue of using ACEIs/ARBs during COVID-19, it is still an area requiring extended investigation to prove. Additionally, a trial evidence of their efficacy and the possible benefit risk analysis of these conventional drugs during COVID-19 in connection with other comorbidities like hypertension, heart failure, and renal disease associated with diabetes should also be addressed.
尽管一些动物研究表明,使用血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂有助于预防和治疗2019冠状病毒病感染的影响,但也有相互矛盾的情况表明,使用这些药物可能会加剧感染的有害状况。由于在2019冠状病毒病期间使用血管紧张素转换酶抑制剂/血管紧张素受体阻滞剂存在矛盾问题,这仍是一个需要进一步研究以证实的领域。此外,还应探讨这些传统药物在2019冠状病毒病期间与高血压、心力衰竭和糖尿病相关肾病等其他合并症相关的疗效试验证据以及可能的效益风险分析。